2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure
Report of the ACC/AHA Task Force on Clinical Practice Guidelines and HFSA
Published 1 September 2016
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Monica M. Colvin, Mark H. Drazner, Gerasimos Filippatos, Gregg C. Fonarow, Michael M. Givertz, Steven M. Hollenberg, JoAnn Lindenfeld, Frederick A. Masoudi, Patrick E. McBride, Pamela N. Peterson, Lynne Warner Stevenson, Cheryl Westlake
J Am Coll Cardiol. 2016 Sep, 68 (13) 1476–1488
An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
The
ACC, the AHA, and the Heart Failure Society of America (HFSA) recognize that the introduction of effective new therapies that potentially affect a large number of patients presents both opportunities and challenges. The introduction of an angiotensin
receptor–neprilysin inhibitor (ARNI) (valsartan/sacubitril) and a sinoatrial node modulator (ivabradine), when applied judiciously, complements established pharmacological and device-based therapies and represents a milestone in the evolution
of care for patients with heart failure (HF). Accordingly, the writing committees of the “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure” and the “2016 ESC Guideline on the Diagnosis and
Treatment of Acute and Chronic Heart Failure” concurrently developed recommendations for the incorporation of these therapies into clinical practice. Working independently, each writing committee surveyed the evidence, arrived at similar conclusions,
and constructed similar, but not identical, recommendations. Given the concordance, the respective organizations simultaneously issued aligned recommendations on the use of these new treatments to minimize confusion and improve the care of patients
with HF.
Related Guidlines
-
2009 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
-
Utilization of Hepatitis C Virus–Infected Organ Donors in Cardiothoracic Transplantation
-
ISHLT Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation
-
The 2016 ISHLT Listing Criteria for Heart Transplantation: A 10-year Update
-
Present Status of Research on Psychosocial Outcomes in Cardiothoracic Transplantation— Review and Recommendations for the Field